Smaller cap COVID-19 vaccine players under pressure on Pfizer data

Investors are apparently reacting to Pfizer and BioNTech’s release of encouraging preliminary early-stage data on COVID-19 vaccine candidate BNT162b1 that showed significant jumps in neutralizing antibodies compared to convalescent plasma.

Members of Big Biopharma are holding up, but others are mostly in the red.

Selected tickers: AstraZeneca (AZN +0.4%), GlaxoSmithKline (GSK +0.3%), Merck (MRK +1.3%), Sanofi (SNY +0.1%), Moderna (MRNA -5.9%), Novavax (NVAX -3.5%), Dynavax Technologies (DVAX -6.4%), Inovio Pharmaceuticals (INO -19.1%), iBio (IBIO -12.4%), Arcturus Therapeutics (ARCT +2.2%), Soligenix (SNGX -0.7%), GeoVax Labs (OTCQB:GOVX -15.5%), Vaxart (VXRT -6.9%), Altimmune (ALT -9.1%), Vir Biotechnology (VIR -7.8%)

https://seekingalpha.com/news/3587833-smaller-cap-covidminus-19-vaccine-players-under-pressure-on-pfizer-data